{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:50:59Z","timestamp":1792381859951,"version":"4.4.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Malignant melanoma is a common source of cutaneous metastases and can occasionally adopt a histological appearance which mimics a primary melanocytic lesion, either benign or malignant. The authors describe a case of new cutaneous deposits of metastatic melanoma in a 70-year-old woman with a prominent admixed lymphocytic infiltrate, imparting a striking resemblance to a halo nevus. The authors believe this appearance was a direct reflection of treatment with pembrolizumab, a humanized antibody against the immune checkpoint inhibitor programmed death-1. With increasing use of immune-modulating drugs, this potential histological mimic may be seen more frequently in the future.<\/jats:p>","DOI":"10.1097\/dad.0000000000000668","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T16:41:42Z","timestamp":1479832902000},"page":"e159-e162","source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition"],"prefix":"10.1097","volume":"38","author":[{"given":"Nathan Tobias","family":"Harvey","sequence":"first","affiliation":[{"name":"Department of Anatomical Pathology, PathWest, QEII Medical Centre, Perth, Western Australia, Australia;"},{"name":"School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia;"},{"name":"School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstie","family":"Macgregor","sequence":"additional","affiliation":[{"name":"Margaret River Surgery, Margaret River, Western Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Paul","family":"Bucat","sequence":"additional","affiliation":[{"name":"Margaret River Surgery, Margaret River, Western Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Andrew","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, PathWest, QEII Medical Centre, Perth, Western Australia, Australia;"},{"name":"School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00000478-199903000-00005","article-title":"Metastatic melanoma to the skin simulating blue nevus","volume":"23","author":"Busam","year":"1999","journal-title":"Am J Surg Pathol."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.1978.01640130031009","article-title":"Epidermotropically metastatic malignant melanoma. Differentiating malignant melanoma metastatic to the epidermis from malignant melanoma primary in the epidermis","volume":"114","author":"Kornberg","year":"1978","journal-title":"Arch Dermatol."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/DAD.0b013e3181b34a19","article-title":"Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum","volume":"32","author":"Plaza","year":"2010","journal-title":"Am J Dermatopathol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1158\/1078-0432.CCR-13-2234","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer\u2013response","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin Cancer Res."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201612000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:06:29Z","timestamp":1694149589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201612000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000668","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}